8-K filing — Morningstar, Inc. (MORN)
Filed: 2026-09-25 AccNo: 0001289419-26-000048 Size: 589 KB Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits
Stocks · News reference
UBS Maintains Buy on Morningstar, Lowers Price Target to $260
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
CME vs. Morningstar: Which Financial Stock Is a Better Buy in 2026?
CME Group and Morningstar are compared as financial infrastructure plays. CME dominates derivatives trading with an impressive 62% net margin and $6.5B revenue, but trades at a premium valuation (forward P/E 22.5). Morningstar offers investment research with lower margins (15.3%) but more attractive valuation (forward P/E 15.5). The author leans toward CME despite valuation concerns due to its superior profitability and dividend, though both stocks have underperformed the S&P 500 over longer periods.
Prediction: Morningstar (MORN) Stock Will Be Worth More Than $13 Billion by 2031 -- 73% Higher Than Its Recent Value. Here's the Math.
Morningstar is projected to reach a market value of $13.2 billion within five years, representing a 73% increase from its recent $7.5 billion valuation. The company has demonstrated consistent 12% annual revenue growth, currently trades at undervalued P/E and price-to-sales ratios, and offers an attractive 13.2% total shareholder yield including dividends and buybacks.
Morningstar's PitchBook Partners With ChatGPT For Financial Services To Bring Expanded Private Market Data
Teams using ChatGPT for Financial Services can access PitchBook's expanded firmographic dataset through the Essential connectorPitchBook, the leading private capital market intelligence platform and a business unit